Adherium Reports 414 Device Shipments and $2.6M Raised Post-Quarter

• 55% quarter-over-quarter growth in device shipments
• iCARE study shows up to 235% improvement in medication adherence
• New patient education call center drives 59% increase in patient activations
• Hailie Care app beta launch set for November 2025
• Post-quarter funding commitments exceed $2.6 million

Commercial Momentum Accelerates

Adherium Limited (ASX, ADR) has delivered a transformational quarter ending September 2025, marked by a 55% increase in device shipments across all channels. The company shipped 414 Remote Patient Monitoring devices in the quarter, contributing to a calendar year total of 2,161 units. This surge was largely driven by the launch of a new patient education call center in August, which significantly boosted patient acquisition and engagement, with new patient activations rising 59% compared to the previous quarter.

The call center has become a pivotal element in scaling Adherium's presence across existing partnerships such as Allergy Partners and SENTA, as well as RPM platform collaborators AMC Health and Tenovi. These partnerships underscore the versatility and growing adoption of the Hailie® Smartinhaler platform in diverse care delivery models across the United States.

Clinical Validation Through iCARE Study

Adherium’s iCARE study, conducted with Intermountain Health and CareCentra, has yielded unprecedented adherence rates, with patients showing up to a 235% improvement over published norms. Approximately 40% of patients achieved adherence levels above 80%, a threshold linked to a 50% reduction in respiratory exacerbations. Notably, 54% of patients remained engaged for over 12 months, far exceeding typical digital health benchmarks.

The study also demonstrated meaningful reductions in hospital admissions and reliance on rescue medications, particularly among high-risk elderly patients. These clinical outcomes not only validate the Hailie platform’s value proposition but also lay the groundwork for AI-driven predictive analytics to anticipate exacerbations, enhancing Adherium’s appeal to payers and health systems.

Product Innovation and Platform Development

Progress continues on the next-generation Hailie Care application, with beta testing completed and an early beta launch scheduled for November 2025. The platform upgrade aims to improve patient engagement, streamline clinician workflows, and integrate AI-driven adherence optimization. Full commercial rollout is planned for early 2026, positioning Adherium to capitalize on its clinical validation and scale its digital health solutions effectively.

Financial Position and Capital Raising

Despite operating cash flow remaining negative at -$4.49 million for the quarter, Adherium has secured critical funding post-quarter. The company received $287,000 from AstraZeneca and $318,000 from option exercises, with commitments from major shareholders expected to bring in an additional $2.42 million by mid-November. This capital injection is vital to support ongoing commercial expansion and product development under the leadership of CEO Dawn Bitz, who has accelerated the company’s US market growth strategy since her appointment in July 2025.

Adherium’s cash on hand stood at $52,000 at quarter-end, underscoring the importance of these funding commitments to sustain operations and execute on its ambitious growth plans.

Bottom Line?

Adherium’s strong commercial and clinical momentum, backed by fresh capital, sets the stage for a pivotal 2026 rollout, but sustaining growth will hinge on continued funding and market adoption.

Questions in the middle?

• How will Adherium convert its strong shipment growth into sustained revenue and profitability?
• What impact will the full publication of the iCARE study have on payer contracts and market penetration?
• Can the Hailie Care platform’s AI capabilities differentiate Adherium in an increasingly competitive digital health landscape?